Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
WEB1 day ago — Oct. 2, 2024, 11:55 PM. J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares ...
Press releases | GSK US
WEBUS FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 — GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GlaxoSmithKline News | GSK News - NewsNow
WEBNewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications.
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US ... - GSK
WEBJul 31, 2023 — GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR ...
GSK raises profit outlook on strong vaccine, HIV drug sales
WEBMay 1, 2024 — GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
GSK to acquire clinical-stage biopharmaceutical company …
WEBMay 31, 2022 — GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones. Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology.
GSK delivers strong 2022 performance with full year sales of £29.3 ...
WEBFeb 1, 2023 — Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines. Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions.
GSK's experimental drug shows promise in reducing severe …
WEBMay 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker...